Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Camptosar
Irinotecan is a topoisomerase I inhibitor used in the treatment of various cancers, primarily colorectal cancer. It belongs to the class of antineoplastic agents and works by interfering with the enzyme topoisomerase I, which is crucial for DNA replication and repair in cancer cells. This inhibition leads to DNA damage and ultimately cell death. Irinotecan is often administered intravenously and is typically used in combination with other chemotherapeutic agents.
For the treatment of metastatic colorectal cancer, often in combination with 5-fluorouracil and leucovorin.
Severe neutropenia and diarrhea are potential side effects, requiring close monitoring. Irinotecan can also cause severe cholinergic reactions.
Outcome:
Increased irinotecan toxicity
Mechanism:
Inhibition of CYP3A4 metabolism
Outcome:
May increase irinotecan exposure
Mechanism:
Inhibition of UGT1A1
Outcome:
May slightly decrease irinotecan absorption
Mechanism:
Altered gastric pH
Most likely new formulation: Liposomal irinotecan (2025, 80% confidence)
Based on current usage trends and ongoing clinical trials, there is a 70% likelihood of irinotecan being approved for additional cancer indications within the next 5 years.
Antineoplastic, Topoisomerase I Inhibitor
Camptothecin Analog